Bempedoic acid is similar with statin therapy at decreasing the risk of a first major vascular event per every 1 mmol/L reduction in LDL-C, according to a post hoc analysis of the CLEAR Outcomes trial ...
In an environment where the cost of inaction eclipses the cost of innovation, evaluating the ROI of risk reduction technology is a critical skill for enterprise leaders. Although enterprise risk is ...
A systematic review of 17 randomized trials found that among high cardiovascular risk individuals, reducing saturated fat was linked to lower all-cause mortality and possible reductions in ...
Daniel Byrne and Ted Bouthiller Jr. offer a remedy for overloaded fire inspectors: include basic fire code instruction in firefighter training to put more eyes and ears on the ground for reducing ...
Oftentimes, first responders are in reaction mode when they respond to incidents. They typically arrive at a scene and assess what needs to be done. But a couple of classes are bringing together Lower ...
"Stop Disasters," an online video game developed by the United Nations Office for Disaster Risk Reduction (UNDRR), teaches young people how to reduce risks linked to flooding, hurricanes and other ...
A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned that although ...
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...
NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved ...
DEAR DR. ROACH: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results